Non-small Cell Lung Cancer Stage III Clinical Trials

48 clinical trials for Non-small Cell Lung Cancer Stage III across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features — RECRUITING · PHASE2
• Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer — RECRUITING · PHASE2
• Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy — RECRUITING · PHASE2
• Pulmonary Rehabilitation in Advanced Lung Cancer Survivors — RECRUITING · PHASE2
• Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients — RECRUITING
• Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab — RECRUITING · PHASE4
• Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients — RECRUITING
• Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly And/or Frail Stage III Non-small-cell Lung Cancer — RECRUITING · NA
• Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer — RECRUITING · PHASE2
• Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) — SUSPENDED · PHASE2
• A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08) — NOT_YET_RECRUITING · PHASE3
• Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer — TERMINATED · NA
• Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC — TERMINATED · PHASE2
• Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment — ACTIVE_NOT_RECRUITING
• Response and Toxicity Prediction by Microbiome Analysis After (Concurrent) Chemoradiotherapy — ACTIVE_NOT_RECRUITING
• Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC — NOT_YET_RECRUITING · PHASE2
• Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study — ACTIVE_NOT_RECRUITING · PHASE2
• Accelerated Radio-Immunotherapy for Lung Cancer — COMPLETED · PHASE2
• Her2-positive Lung Cancer Treated With Dedicated Drug — COMPLETED · PHASE2
• Combining ICI With SBRT or HypoFrx-RT for ES NSCLC — OTHER · PHASE1
• Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy — OTHER · PHASE3
• A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy — OTHER · PHASE2
• The Association of MicroRNA21-155 Levels With Acute Side Effects In Patients With Stage III NSCLC With Definitive CRT — COMPLETED
• A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer — COMPLETED · PHASE3
• Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029） — COMPLETED · PHASE2
• Quantifying Systemic Immunosuppression to Personalize Cancer Therapy — WITHDRAWN · NA
• Pilot Study of a Novel Type of CT Scan to Assess Treatment Response During Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer — COMPLETED
• Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC — NOT_YET_RECRUITING · PHASE2
• NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma — COMPLETED · PHASE2
• A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer — OTHER · PHASE2
• High Intensity Functional Image Guided Vmat Lung Evasion — COMPLETED · NA
• Dose-painting Radiation for LA-NSCLC — OTHER · NA
• Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC — OTHER · PHASE2
• Tumor Mutational Burden in Lung Cancer Patients — TERMINATED
• Biomarkers of Stage III Locally Advanced Unresectable Non-small-cell Lung Cancer — OTHER
• A Real-world Study of Durvalumab for Lung Cancer in China — OTHER
• A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC) — TERMINATED · PHASE1
• Efficacy and Safety of CRT, Durvalumab and Surgery for SST — NOT_YET_RECRUITING · PHASE3
• Oncoxin® and Quality of Life in Cancer Patients — COMPLETED · PHASE4
• Prognostic Evaluation of Tumor Volume and Its Changes in Radical Radiotherapy of Advanced NSCLC — COMPLETED
• T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure — COMPLETED
• EGFR Mutations on ctDNA in Patients With Advanced NSCLC — COMPLETED
• ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC — OTHER
• Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation — OTHER · PHASE2
• Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC) — WITHDRAWN · PHASE2
• An International Study on the Use of PET/CT in Radiotherapy Planning in Low and Middle Income Countries — OTHER

Refine this search